SciTech Second Quarterly 2025 Newsletter

NEWS PROVIDED BY
SciTech Development
11 Jun, 2025, 09:00 ET

DETROIT, Jun. 11, 2025 — Read the latest Second Quarterly 2025 newsletter here.  This captures all the updates including strong early data in T-cell lymphoma, FDA approval on our second IND for small cell lung cancer trial, expanded manufacturing, $20M Series A launch, and a growing wave of investor and clinical support.

About SciTech Development, Inc.

SciTech Development, Inc. is a clinical-stage biotechnology company dedicated to the development of novel therapies for the treatment of cancer. SciTech is focused on advancing its clinical programs to bring innovative and effective cancer treatments to patients worldwide.

For more information about SciTech Development and its clinical programs, please visit www.SciTechSDP.com.

This press release may contain forward-looking statements that are subject to risks and uncertainties. These statements are based on current expectations and assumptions and are not guarantees of future performance.

CONTACT

SciTech Development: Investor Relations
David Schaffer
DRS@SciTechDevelopment.com